November 2017 Issue Table Of Contents

From The Editor

• Why Semantics Matter In Pharma

Feature Articles

• Industry Explorers Blaze On
• Can We Make Innovative Medicines Affordable?
• From Startup To Acquisition By Lilly, And Everything In Between
• What Makes Roche’s Approach To Partnering Unusual

Capitol Perspectives

• Republican Dysfunction Could Result In Radical Democratic Health Agenda

Companies To Watch

• Abivax

Inside The Industry

• The Impact Of CETA On The Pharmaceutical Industry
• Don’t Have A Chief Innovation Officer? Get One … Now
• Information Management Strategies To Improve Data Integrity During M&As
• More Gender-Based Analysis Needed In Medical Device Studies
• Pet Medicines: Smaller Market, Lower Costs, Greater Margins
• Will Value-Based Drug Pricing Work?

Leadership Lessons

• Competitive Advantage Is Not What It Used To Be

Ask The Board

• What Are You Working On Outside Of Your Role As Plant Manager For MSD Pharmaceutical Operations At Merck?
• What Is Your Approach To Balancing Your Dual Responsibilities Of Serving As Chief Medical Officer And Coleader Of The Medicines Development Unit (MDU)?
• What Is Your Opinion On The FDA´S New Approach To Approving Drugs Based On Their Genetic Profiles?

Reader Feedback

• Reader Feedback